Volume 14 Supplement 2
Detection rate of Pompe disease in undiagnosed neuromuscular patients from four major centres in the UK - results of a 12 month prospective audit
© Willis et al; licensee BioMed Central Ltd. 2013
Published: 29 May 2013
This 12-month audit (conducted between 1st July 2011 to 30th June 2012) was designed following a retrospective audit in a specialist neuromuscular centre (UK) using DBS testing to identify late-onset Pompe disease. The objective was to screen all patients with an unknown diagnosis presenting with a limb girdle pattern of muscle weakness +/- respiratory symptoms +/- scoliosis +/- rigid spine that were seen in the clinic, including new referrals and follow-up patients. Our goal is to improve the detection rate of Pompe disease and to initiate early treatment in clinical practice. To that end, this audit has been extended through June 2013.
Out of 102 patients, six positive tests were obtained on DBS (5.9%), one of which was a false positive in a patient aged 40 years (CK>1000, symptoms from adulthood, resp. problems; ventilated at night). Five positive cases were subsequently confirmed (4.9% - plus one additional case identified as a family member). These cases will be reported in detail. If not in the audit, these patients would not have been diagnosed with Pompe disease on the basis of their symptoms.
Pompe disease is a progressive, debilitating and often fatal neuromuscular disorder that presents with a continuum of clinical phenotypes that vary with regards to organ involvement, age of onset, disease severity and rate of progression. Early diagnosis is key to implementing early disease modifying treatment. Whilst all these patients detected have some of the features that have been documented in Pompe disease, it is vital that clinicians are alerted to the subtle presentation that late onset Pompe can have. DBS is a rapid test that improves the time to diagnosis, and hence, time to treatment, as suggested in the International Consensus meeting .
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.